ArticleJournal of clinical and translational science2023
A framework for assessing clinical trial site readiness.
Article in Journal of clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Measuring What Matters in Trial Operations: Development and Validation of the Clinical Trial Site Performance Measure.Journal of clinical medicine · 2025Article
- Nurse Liaison Support to Safeguard the Scientific Rigor of Multisite Clinical Trials: Qualitative Findings From Communications Between Clinical Research Professionals.Cancer nursing · 2025Article
- Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy.World journal of clinical oncology · 2025Article
- Selecting trial centers using a standardized, automated site assessment survey instrument (SASI).Contemporary clinical trials · 2024Article
- Successful transport across continents of GMP-manufactured and cryopreserved culture-expanded human fetal liver-derived mesenchymal stem cells for use in a clinical trial.Regenerative therapy · 2024Article
- Clinical trial site readiness for decentralized trials - fitting trials into today's world.Journal of clinical and translational science · 2024Article
- Scientia pro bono humani generis: Science for the benefit of humanity.Journal of clinical and translational science · 2024Article
- Site readiness practices for clinical trials - considerations for CTSA hubs.Journal of clinical and translational science · 2023Article
- Diversity, equity, inclusion, and access are necessary for clinical trial site readiness.Journal of clinical and translational science · 2023Article
- Patterns of Enrollment of Traditionally Underrepresented Patients in ECOG-ACRIN Sponsored Breast Cancer Therapeutic Clinical Trials.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
Abstract
Clinical trial processes are unnecessarily inefficient and costly, slowing the translation of medical discoveries into treatments for people living with disease. To reduce redundancies and inefficiencies, a group of clinical trial experts developed a framework for clinical trial site readiness based on existing trial site qualifications from sponsors. The site readiness practices are encompassed within six domains: research team, infrastructure, study management, data collection and management, quality oversight, and ethics and safety. Implementation of this framework for clinical trial sites would reduce inefficiencies in trial conduct and help prepare new sites to enter the clinical trials enterprise, with the potential to improve the reach of clinical trials to underserved communities. Moreover, the framework holds benefits for trial sponsors, contract research organizations, trade associations, trial participants, and the public. For novice sites considering future trials, we provide a framework for site preparation and the engagement of stakeholders. For experienced sites, the framework can be used to assess current practices and inform and engage sponsors, staff, and participants. Details in the supplementary materials provide easy access to key regulatory documents and resources. Invited perspective articles provide greater depth from a systems, DEIA (diversity, equity, inclusion, and accessibility) and decentralized trials perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.